The endothelin system and its potential as a therapeutic target in cardiovascular disease

Pharmacology & Therapeutics
G A Gray, D J Webb

Abstract

Endothelin (ET)-1, an endothelium-derived peptide, is the most potent vasoconstrictor agent described to date. ET-1 also has positive inotropic and chronotropic effects in the heart and is a co-mitogen in both cardiac and vascular myocytes. The major elements of the system involved in formation of ET-1 and its isopeptides, as well as the receptors mediating their effects, have been cloned and characterised. Antagonists of the ET receptors are now available, and selective inhibitors of the ET-converting enzymes are being developed. Early studies using receptor antagonists support the involvement of ET-1 in the pathophysiology of several cardiovascular diseases. The relative merits of ET-converting enzyme inhibitors and receptor antagonists for the treatment of cardiovascular disease are discussed.

References

Mar 12, 1976·Science·P R CaldwellR L Soffer
Dec 1, 1992·Journal of Cardiovascular Pharmacology·M K BazilR L Webb
Jan 1, 1992·European Journal of Clinical Investigation·H VierhapperW Waldhäusl
Apr 15, 1992·Biochemical and Biophysical Research Communications·S MorelandJ T Hunt
Apr 30, 1992·Biochemical and Biophysical Research Communications·M TakaiT Okada
Jul 31, 1992·Biochemical and Biophysical Research Communications·M ClozelR Osterwalder
Aug 21, 1992·Journal of Medicinal Chemistry·W L CodyS J Haleen
Sep 1, 1992·European Journal of Pharmacology·J P Burbach, O C Meijer
Mar 1, 1992·Journal of Cardiovascular Pharmacology·P H DeleuzeD Y Loisance
Sep 1, 1992·European Heart Journal·T F Lüscher
Oct 1, 1992·The American Journal of the Medical Sciences·D J HayzerM S Runge
Dec 1, 1992·Clinical Pharmacology and Therapeutics·N S AndrawisD R Abernethy
Nov 1, 1992·British Journal of Pharmacology·M J SumnerI S Watts
Oct 1, 1992·The Journal of Antibiotics·H OhashiJ Mochizuki
Nov 20, 1992·Regulatory Peptides·C FagnyM Deschodt-Lanckman
Aug 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·S KawJ R Vane
Apr 1, 1992·European Journal of Clinical Investigation·O F WagnerW Waldhäusl
Apr 1, 1992·Circulation·J J McMurrayJ J Morton
Mar 16, 1992·Biochemical and Biophysical Research Communications·R L PanekS T Rapundalo
Mar 1, 1992·American Journal of Hypertension·T HaakK H Usadel
Jun 25, 1992·Annals of Internal Medicine·S T O'KeeffeW P Beetham

❮ Previous
Next ❯

Citations

Jan 12, 1999·Biulleten' eksperimental'noĭ biologii i meditsiny·V F PozdnevN A Medvedeva
Sep 18, 2010·Cellular and Molecular Life Sciences : CMLS·Yoshifumi Kawanabe, Surya M Nauli
Jan 4, 2008·Naunyn-Schmiedeberg's Archives of Pharmacology·Iyuki NamekataHikaru Tanaka
May 4, 2004·Journal of Chemical Neuroanatomy·V NaidooD M Raidoo
May 24, 2000·European Journal of Pharmacology·J E Tanus-SantosH Moreno
Jun 14, 2000·European Journal of Pharmacology·J E Tanus-SantosH Moreno
Sep 2, 2000·European Journal of Pharmacology·A SalamoussaS Ventura
Jul 13, 2001·Pharmacology & Therapeutics·S Naicker, K D Bhoola
Mar 24, 1998·Trends in Pharmacological Sciences·D J WebbM Yanagisawa
Jan 12, 2001·Journal of the American College of Cardiology·P A MacCarthyP H Groves
Sep 6, 2003·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Rudolf BergerRichard Pacher
Aug 8, 2002·Kidney International·Eckhart BüssemakerPeter Gross
Aug 6, 1998·British Journal of Obstetrics and Gynaecology·T Y Khong
Jan 31, 2009·International Journal of Clinical Practice. Supplement·D BondermanI M Lang
Jun 8, 2012·International Journal of Endocrinology·Kazuhiro Takahashi
Nov 19, 2009·Drug Design, Development and Therapy·Brian Casserly, James R Klinger
Mar 7, 2006·Kidney International·K van der ZanderP W de Leeuw
May 26, 2005·Brain Research. Brain Research Reviews·Lyle W Ostrow, Frederick Sachs
May 21, 2004·British Journal of Clinical Pharmacology·Stephen J LeslieDavid J Webb
May 9, 2009·British Journal of Pharmacology·S K WalshC L Wainwright
Nov 30, 2004·Expert Opinion on Investigational Drugs·Antonio Jimeno, Michael Carducci
May 1, 1997·Expert Opinion on Investigational Drugs·S J Haleen, X M Cheng
Nov 4, 2000·Expert Opinion on Investigational Drugs·T KnollP Rohmeiss
May 4, 2011·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Ariadne AvellinoGregory J Fermann
Oct 24, 2014·Journal of Human Hypertension·O A Gutiérrez-AdrianzénC R M Rodrigues Sobrinho
Aug 2, 2001·The Journal of Thoracic and Cardiovascular Surgery·C JoffsF G Spinale
Mar 11, 2006·Kidney International·V M CampeseD Sandee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.